Balagué C, Vela S, Targarona E M, Gich I J, Muñiz E, D'Ambra A, Pey A, Monllau V, Ascaso E, Martinez C, Garriga J, Trias M
Service of Surgery, Hospital de Sant Pau, C/Padre Claret 167, 08025, Barcelona, Spain,
Surg Endosc. 2006 Aug;20(8):1208-13. doi: 10.1007/s00464-005-0445-6. Epub 2006 Jul 24.
Laparoscopic splenectomy (LS) offers better short-term results than open surgery for the treatment of immune thrombocytopenic purpura (ITP), but long-term follow-up is required to ensure its efficacy. The remission rate after splenectomy ranges from 49 to 86% and the factors that predict a successful response to surgical management have not been clearly defined. The goal of this study was to determine the preoperative factors that predict a successful outcome following LS.
From February 1993 to December 2003, LS was consecutively performed in a series of 119 nonselected patients diagnosed with ITP (34 men and 85 women; mean age, 41 years), and clinical results were prospectively recorded. Postoperative follow-up was based on clinical records, follow-up data provided by the referring hematologist, and a phone interview with the patient and/or relative. Univariate and multivariate analyses were performed for clinical preoperative variables to identify predictive factors of success following LS.
Over a mean period of 33 months, 103 patients (84%) were available for follow-up with a remission rate of 89% (92 patients, 77 with complete remission with platelet count > 150,000). Eleven patients did not respond to surgery (platelet count < 50,000). Mortality during follow-up was 2.5% (two cases not related to hematological pathology and one case without response to splenectomy). Preoperative clinical variables evaluated to identify predictive factors of response to surgery were sex, age, treatment (corticoids alone or associated with Ig or chemotherapy), other immune pathology, duration of disease, and preoperative platelet count. In a subgroup of 52 patients, we also evaluated the type of autoantibodies and corticoid doses required to maintain a platelet count > 50,000. Multivariate analysis showed that none of the variables evaluated could be considered as predictive factors of response to LS due to the high standard error.
Long-term clinical results show that LS is a safe and effective therapy for ITP. However, a higher number of nonresponders is needed to determine which variables predict response to LS for ITP.
对于免疫性血小板减少性紫癜(ITP)的治疗,腹腔镜脾切除术(LS)比开放手术具有更好的短期效果,但需要长期随访以确保其疗效。脾切除术后的缓解率在49%至86%之间,而预测手术治疗成功反应的因素尚未明确界定。本研究的目的是确定预测LS术后成功结果的术前因素。
从1993年2月至2003年12月,对一系列119例未经选择的诊断为ITP的患者(34例男性和85例女性;平均年龄41岁)连续进行LS,并前瞻性记录临床结果。术后随访基于临床记录、转诊血液科医生提供的随访数据以及对患者和/或亲属的电话访谈。对术前临床变量进行单因素和多因素分析,以确定LS术后成功的预测因素。
在平均33个月的时间里,103例患者(84%)可供随访,缓解率为89%(92例患者,77例完全缓解,血小板计数>150,000)。11例患者对手术无反应(血小板计数<50,000)。随访期间的死亡率为2.5%(2例与血液学病理无关,1例对脾切除术无反应)。为确定手术反应的预测因素而评估的术前临床变量包括性别、年龄、治疗(单独使用皮质类固醇或与免疫球蛋白或化疗联合使用)、其他免疫病理、疾病持续时间和术前血小板计数。在52例患者的亚组中,我们还评估了自身抗体类型和维持血小板计数>50,000所需的皮质类固醇剂量。多因素分析表明,由于标准误差较高,所评估的变量均不能被视为LS反应的预测因素。
长期临床结果表明,LS是治疗ITP的一种安全有效的疗法。然而,需要更多无反应者来确定哪些变量可预测ITP对LS的反应。